Nanotheranostics 2023; 7(3):270-280. doi:10.7150/ntno.81557 This issue Cite

Research Paper

Hybrid Inorganic Complexes as Cancer Therapeutic Agents: In-vitro Validation

Murlidhar A Betallu1✉, Shaileshkumar R Bhalara2, Kailash B Sapnar3, Vijay B Tadke1, Keerti Meena5, Ananya Srivastava6, Gopal C Kundu2,4, Mahadeo Gorain2✉

1. Department of Chemistry, Fergusson College, Pune, 411004, Maharashtra, India
2. Laboratory of Tumor Biology, Angiogenesis and Nanomedicine Research, National Centre for Cell Science, Pune, 411007, Maharashtra, India
3. Department of Physics, Fergusson College, Pune, 411004, Maharashtra, India
4. School of Biotechnology and Kalinga Institute of Medical Sciences (KIMS), KIIT Deemed to be University, Institute of Eminence, Bhubaneswar 751 024, India
5. BP Lab, Jamdoli, Jaipur, Rajasthan 302031, India
6. Department of Chemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India

Citation:
Betallu MA, Bhalara SR, Sapnar KB, Tadke VB, Meena K, Srivastava A, Kundu GC, Gorain M. Hybrid Inorganic Complexes as Cancer Therapeutic Agents: In-vitro Validation. Nanotheranostics 2023; 7(3):270-280. doi:10.7150/ntno.81557. https://www.ntno.org/v07p0270.htm
Other styles

File import instruction

Abstract

Graphic abstract

A series of novel mixed transition metal-Magnesium tartarate complexes of general formulation [MMg(C4H4O6)2.xH2O] (where M = Mn, Fe, Co, Ni, Cu and Zn) is prepared with bidentate tartarate ligand. The synthesized complexes (C1 to C6) are characterized by various analytical techniques such as Elemental analysis, Thermo gravimetric analysis, FT-IR Spectroscopy, X-ray Diffraction, Magnetic susceptibility study etc. All complexes exhibit the composition MMgL2 where M = Mn(II), Fe(II), Co(II), Ni(II), Cu(II) and Zn(II) and L = bidentate tartarate ligand. Analytical data reveals all complexes possesses 1:1 (metal: ligand) ratio. FT-IR spectral study shows that bidentate tartarate ligand coordinate with metal ion in a bidentate manner through two oxygen atoms. Thermo gravimetric analysis of all complexes shows that degradation curves of complexes agrees with recommended formulae of the complexes. X-ray diffraction technique suggests that all complexes (C1 to C6) are polycrystalline in nature. All newly synthesized metal tartarate complexes and ligand were screened in vitro for their anticancer activity against human breast cancer (MDA-MB-231) cell line. The bioassays of all these complexes showed C3 (Co) and C5 (Cu) Mg-tartarate complexes contains maximum antiproliferative activity at 200 µg/ml concentration on MDA-MB-231 cells as compared to other complexes. MDA-MB-231 cells treated with C3 (Co) and C5 (Cu) Mg-tartarate complexes also showed inhibition in cell migration.

Keywords: Transition - magnesium tartarate complexes, bidentate tartarate ligand, octahedral tartarate complexes, anticancer activity.


Citation styles

APA
Betallu, M.A., Bhalara, S.R., Sapnar, K.B., Tadke, V.B., Meena, K., Srivastava, A., Kundu, G.C., Gorain, M. (2023). Hybrid Inorganic Complexes as Cancer Therapeutic Agents: In-vitro Validation. Nanotheranostics, 7(3), 270-280. https://doi.org/10.7150/ntno.81557.

ACS
Betallu, M.A.; Bhalara, S.R.; Sapnar, K.B.; Tadke, V.B.; Meena, K.; Srivastava, A.; Kundu, G.C.; Gorain, M. Hybrid Inorganic Complexes as Cancer Therapeutic Agents: In-vitro Validation. Nanotheranostics 2023, 7 (3), 270-280. DOI: 10.7150/ntno.81557.

NLM
Betallu MA, Bhalara SR, Sapnar KB, Tadke VB, Meena K, Srivastava A, Kundu GC, Gorain M. Hybrid Inorganic Complexes as Cancer Therapeutic Agents: In-vitro Validation. Nanotheranostics 2023; 7(3):270-280. doi:10.7150/ntno.81557. https://www.ntno.org/v07p0270.htm

CSE
Betallu MA, Bhalara SR, Sapnar KB, Tadke VB, Meena K, Srivastava A, Kundu GC, Gorain M. 2023. Hybrid Inorganic Complexes as Cancer Therapeutic Agents: In-vitro Validation. Nanotheranostics. 7(3):270-280.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image